Sensei Biotherapeutics Inc.

https://www.senseibio.com

LinkedIn: https://linkedin.com/company/sensei-bio

Sensei Biotherapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and delivery of precision immunotherapies. The company has developed a unique phage-based platform, Immunophage™, that enables the generation of immune activating agents that fully engage the immune system. Its most advanced program, SNS-301, is currently enrolling patients in Phase 2 clinical trials. The company brings together scientific leaders in biology, immunology, and oncology along with a highly experienced management team and scientific advisors. *

	Start	2020-10-07 existent
	Group	Sensei Biotherapeutics (Group)
	Industry	biopharmaceutical
	Industry 2	cancer immunotherapy (immuno-oncology, I-O)
	Person	Celebi, John (Sensei Biotherapeutics 202010 CEO)
	Person 2	Peyer, James (Apollo Ventures 201902 Managing Partner)

	Region	Gaithersburg, MD
	Country	United States (USA)
	Street	620 Professional Drive
	City	20879 Gaithersburg, MD
	Tel	+1-240-243-8000
		Address record changed: 2024-01-05

Basic data	Employees	n. a.

		* Document for »About Section«: Sensei Biotherapeutics, Inc.. (10/7/20). "Press Release: Sensei Biotherapeutics Announces $28.5 Million Financing To Advance Clinical Pipeline and Immunophage Platform Targeting Multiple Cancers". Boston, MA & Gaithersburg, MD.

		Record changed: 2023-07-10